ALLSHWIL, SWITZERLAND / ACCESSWIRE / May 12, 2022 / Spexis AG (SIX: SPEX) today announced that that the company will present at BioEquity Europe, taking place May 17 & 18, 2022. Jeff Wager, CEO of Spexis, will provide an overview of the company and its pipeline and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.
The presentation is now available to conference registrants. For more information on the conference, visit the BioEquity website .
For further information please contact:
Chief Financial Officer
+41 61 567 16 00
Ph: +49 89 210 228 0
Dr. Stephan Feldhaus
Feldhaus & Partner
+41 79 865 92 56
Dr. Brigitte Keller/Laurie Doyle
Europe: +49 89 210 228 0
U.S.: +1 339 832 0752
Spexis is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland, focused on rare diseases and oncology. The current pipeline of the company is a combination of two legacy companies, Polyphor AG and EnBiotix, Inc. (Boston, MA, USA) which merged in December 2021. The combined company has been renamed to Spexis AG and is trading on the SIX Swiss Exchange under the symbol SIX:SPEX. For further information please visit: www.spexisbio.com .
This press release contains forward-looking statements which are based on current assumptions and forecasts of Spexis management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Spexis' results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only as of the date of this communication. Spexis disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE: Polyphor AG